Ten Capital Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Ten Capital Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-161	Closed	-$22.2K	–	484
2023 Q1	$22.2K	Hold	161	–	–	0.01%	300
2022 Q4	$20.9K	Hold	161	–	–	0.01%	258
2022 Q3	$18K	Hold	161	–	–	0.01%	255
2022 Q2	$12K	Hold	161	–	–	0.01%	250
2022 Q1	$13K	Hold	161	–	–	0.01%	272
2021 Q4	$14K	Buy	161 +62	+63%	+$5.3K	0.01%	270
2021 Q3	$9K	Hold	99	–	–	﹤0.01%	281
2021 Q2	$8K	Sell	99 -150	-60%	-$11.4K	﹤0.01%	336
2021 Q1	$18K	Buy	249 +25	+11%	+$2.31K	﹤0.01%	229
2020 Q4	$38K	Buy	+224	New	+$33.2K	0.01%	182

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ten Capital Wealth Advisors's SRPT Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 161 shares — an estimated $22.2K sold.

Ten Capital Wealth Advisors first reported a position in SRPT in Q4 2020 and held it in 10 quarters. The position peaked at $38K in Q4 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Ten Capital Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Ten Capital Wealth Advisors sold 161 Sarepta Therapeutics shares in Q2 2023, an estimated $22.2K.
Ten Capital Wealth Advisors first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 10 quarters.
Ten Capital Wealth Advisors's Sarepta Therapeutics position peaked at $38K in Q4 2020.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.